CS
VTVT icon

Candriam SCA’s vTv Therapeutics VTVT Stock Holding History

Candriam SCA’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,250
Closed -$541K – 791
2017
Q4 		$541K Sell
2,250
-1,250
-36% -$280K 0.01% 664
2017
Q3 		$837K Hold
3,500
– – 0.01% 598
2017
Q2 		$696K Hold
3,500
– – 0.01% 627
2017
Q1 		$917K Buy
+3,500
New +$798K 0.02% 576

Other funds holding VTVT

GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Candriam SCA's VTVT Position: Q1 2018 in Review

Candriam SCA sold out of vTv Therapeutics (VTVT) in Q1 2018, closing a stake of 2,250 shares — an estimated $541K sold.

Candriam SCA first reported a position in VTVT in Q1 2017 and held it in 4 quarters. The position peaked at $917K in Q1 2017. 41 funds tracked by Wall St. Rank hold VTVT as of Q1 2018.

  • Candriam SCA reported no remaining vTv Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Candriam SCA sold 2,250 vTv Therapeutics shares in Q1 2018, an estimated $541K.
  • Candriam SCA first reported a position in vTv Therapeutics in Q1 2017 and held it in 4 quarters.
  • Candriam SCA's vTv Therapeutics position peaked at $917K in Q1 2017.
  • 41 funds tracked by Wall St. Rank held vTv Therapeutics as of Q1 2018.

Based on Candriam SCA's 13F filing for Q1 2018, filed 9 May 2018.